Nephrogenic Diabetes Insipidus Associated with Foscarnet - A Case Report [letter]
| Title: | Nephrogenic Diabetes Insipidus Associated with Foscarnet - A Case Report [letter] |
|---|---|
| Authors: | Conn, Jennifer; Colman, Peter; Brown, Graham; Street, Alan; Bate, Katherine |
| Publisher: | Journal of Antimicrobial Chemotherapy |
| Date Published: | June 01, 1996 |
| Reference Number: | 23 |
| To return to this page, use your "back" key. |
This translation by the NDI Foundation is to assist the lay reader. To provide a clear, accessible interpretation of the original article, we eliminated or simplified some technical detail and complicated scientific language. We concentrated our translation on those aspects of the article dealing directly with NDI. The NDI Foundation thanks the researchers for their work toward understanding and more effectively treating this disorder.
© Copyright NDI Foundation 2007 (JC)
The authors suspected the patient had developed nephrogenic diabetes insipidus (NDI) in response to foscarnet. Because of the delicacy of the patient's health, he was not given a water deprivation test to help confirm this, but the patient's urine and serum concentrations were indicative of NDI. In NDI, the kidneys do not pick up the hormonal signal of the antidiuretic hormone, vasopressin (VP). This results in an inability to concentrate urine, and leads to excessive thirst and urination.
The patient was infused with desmopressin, an analog of the naturally occurring VP. Eight days after the foscarnet was discontinued, the patient no longer experienced excessive thirst and urination. No other cause for the NDI apart from the foscarnet could be found.
The mechanism of foscarnet-induced NDI is not clearly understood. There had been, however, a previous report of another AIDS patient who experienced it. The authors conclude that NDI is a rare but important side effect of the use of foscarnet in the management of CMV retinitis.



